Drug Interactions between cinacalcet and leniolisib
This report displays the potential drug interactions for the following 2 drugs:
- cinacalcet
- leniolisib
Interactions between your drugs
cinacalcet leniolisib
Applies to: cinacalcet and leniolisib
GENERALLY AVOID: Coadministration of leniolisib may increase plasma levels of substrates of the CYP450 1A2 isoenzyme. According to in vitro studies, leniolisib is a time-dependent irreversible inhibitor of CYP450 1A2. However, clinical data are not available.
MANAGEMENT: Caution and monitoring are recommended if leniolisib is to be administered in combination with CYP450 1A2 substrates. According to the manufacturer of leniolisib, its concomitant use of CYP450 1A2 substrates with a narrow therapeutic index should generally be avoided.
References (2)
- (2023) "Product Information. Joenja (leniolisib)." Pharming Healthcare Inc.
- (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.
Drug and food interactions
cinacalcet food
Applies to: cinacalcet
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of cinacalcet. According to the product labeling for cinacalcet, administration with a high-fat meal increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of cinacalcet by 82% and 68%, respectively, compared to administration in the fasting state. The Cmax and AUC were increased 65% and 50%, respectively, when cinacalcet was administered with a low-fat meal compared to fasting.
MANAGEMENT: To ensure maximal oral absorption, cinacalcet should be administered with or immediately after a meal. The tablets should be taken whole and not divided or crushed.
References (1)
- (2004) "Product Information. Sensipar (cinacalcet)." Amgen USA
leniolisib food
Applies to: leniolisib
MONITOR: Coadministration with inhibitors of CYP450 3A4 including grapefruit or grapefruit juice may increase the plasma concentrations of leniolisib, which undergoes extensive CYP450 3A4-mediated first-pass metabolism in the gut wall and liver. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of leniolisib. Some authorities recommend to avoid grapefruit products during leniolisib treatment (UK).
References (1)
- (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.